
Joost C M Meijers

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4406003/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Iron-Driven Alterations on Red Blood Cell-Derived Microvesicles Amplify Coagulation during Hemolysis via the Intrinsic Tenase Complex. Thrombosis and Haemostasis, 2022, 122, 080-091.	3.4	3
2	Major bleeding during oral anticoagulant therapy associated with factor V activation by factor Xa. Journal of Thrombosis and Haemostasis, 2022, 20, 328-338.	3.8	4
3	Coagulation in gout: is there a link with disease activity?. Clinical Rheumatology, 2022, 41, 1809-1815.	2.2	1
4	VhH antiâ€ŧhrombomodulin clone 1 inhibits TAFI activation and enhances fibrinolysis in human whole blood under flow. Journal of Thrombosis and Haemostasis, 2022, 20, 1213-1222.	3.8	2
5	Basic science research opportunities in thrombosis and hemostasis: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2022, 20, 1496-1506.	3.8	5
6	A FRET-based assay for the quantitation of the thrombin-factor XI interaction. Thrombosis Research, 2022, 214, 23-28.	1.7	3
7	Reversing direct factor Xa or thrombin inhibitors: Factor V addition to prothrombin complex concentrate is beneficial in vitro. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12699.	2.3	4
8	Antiâ€Î²2â€glycoprotein I and antiâ€prothrombin antibodies cause lupus anticoagulant through different mechanisms of action. Journal of Thrombosis and Haemostasis, 2021, 19, 1018-1028.	3.8	22
9	Structureâ€function of anticoagulant TIXâ€5, the inhibitor of factor Xaâ€mediated FV activation. Journal of Thrombosis and Haemostasis, 2021, 19, 1697-1708.	3.8	1
10	Induced normothermia ameliorates the procoagulant host response in human endotoxaemia. British Journal of Anaesthesia, 2021, 126, 1111-1118.	3.4	3
11	Iron-Driven Alterations on Red Blood Cell-Derived Microvesicles Amplify Coagulation during Hemolysis via the Intrinsic Tenase Complex. Thrombosis and Haemostasis, 2021, , .	3.4	3
12	Aprotinin Inhibits Thrombin Generation by Inhibition of the Intrinsic Pathway, but is not a Direct Thrombin Inhibitor. TH Open, 2021, 05, e363-e375.	1.4	2
13	Transient ST-elevation myocardial infarction versus persistent ST-elevation myocardial infarction. An appraisal of patient characteristics and functional outcome. International Journal of Cardiology, 2021, 336, 22-28.	1.7	4
14	Development of a Plasma-Based Assay to Measure the Susceptibility of Factor V to Inhibition by the C-Terminus of TFPIα. Thrombosis and Haemostasis, 2020, 120, 055-064.	3.4	4
15	Complement C5 Contributes to Brain Injury After Subarachnoid Hemorrhage. Translational Stroke Research, 2020, 11, 678-688.	4.2	24
16	Linkage analysis combined with whole-exome sequencing identifies a novel prothrombin (<i>F2</i>) gene mutation in a Dutch Caucasian family with unexplained thrombosis. Haematologica, 2020, 105, e370-e372.	3.5	6
17	Antisense Inhibition of Prekallikrein to Control Hereditary Angioedema. New England Journal of Medicine, 2020, 383, 1242-1247.	27.0	28
18	MiR-223-3p and miR-122-5p as circulating biomarkers for plaque instability. Open Heart, 2020, 7, e001223.	2.3	45

#	Article	IF	CITATIONS
19	Prediction of cerebral venous thrombosis with a new clinical score and D-dimer levels. Neurology, 2020, 95, e898-e909.	1.1	18
20	Nomenclature of factor XI and the contact system. Journal of Thrombosis and Haemostasis, 2019, 17, 2216-2219.	3.8	11
21	Coagulation Factor XIII in Cerebral Venous Thrombosis. TH Open, 2019, 03, e227-e229.	1.4	3
22	Hydrogenâ€deuterium exchange mass spectrometry highlights conformational changes induced by factor XI activation and binding of factor IX to factor XIa. Journal of Thrombosis and Haemostasis, 2019, 17, 2047-2055.	3.8	16
23	In vitro evaluation of factor IX as novel treatment for factor XI deficiency. Blood, 2019, 134, 573-575.	1.4	7
24	Zika Virus Infection Induces Elevation of Tissue Factor Production and Apoptosis on Human Umbilical Vein Endothelial Cells. Frontiers in Microbiology, 2019, 10, 817.	3.5	22
25	Design and characterization of α1-antitrypsin variants for treatment of contact system–driven thromboinflammation. Blood, 2019, 134, 1658-1669.	1.4	20
26	An anticoagulant that does not cause bleeding – an abrupt stop on the road to the Holy Grail. Journal of Thrombosis and Haemostasis, 2019, 17, 2019-2021.	3.8	2
27	Albumin plasma exchange for life-threatening angioedema with normal C1-inhibitor. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1360-1361.	3.8	2
28	Transfusion of autologous extracellular vesicles from stored red blood cells does not affect coagulation in a model of human endotoxemia. Transfusion, 2018, 58, 1486-1493.	1.6	7
29	Chemical Footprinting Reveals Conformational Changes Following Activation of Factor XI. Thrombosis and Haemostasis, 2018, 118, 340-350.	3.4	8
30	Prochemerin processing by factor XIa. Blood, 2018, 131, 275-276.	1.4	0
31	Coagulation and fibrinolysis in hyperparathyroidism secondary to vitamin D deficiency. Endocrine Connections, 2018, 7, 325-333.	1.9	10
32	Coagulopathy in Zellweger spectrum disorders: a role for vitamin K. Journal of Inherited Metabolic Disease, 2018, 41, 249-255.	3.6	7
33	Hemostatic profile under fluid resuscitation during rivaroxaban anticoagulation: an in vitro survey. Transfusion, 2018, 58, 3014-3026.	1.6	5
34	Activation of coagulation and endothelium with concurrent impairment of anticoagulant mechanisms in patients with typhoid fever. Journal of Infection, 2018, 77, 60-67.	3.3	9
35	Abnormal coagulation and enhanced fibrinolysis due to lysinuric protein intolerance associates with bleeds and renal impairment. Haemophilia, 2018, 24, e312-e321.	2.1	13
36	FactorÂXI promotes hemostasis in factorÂIXâ€deficient mice. Journal of Thrombosis and Haemostasis, 2018, 16, 2044-2049.	3.8	16

#	Article	IF	CITATIONS
37	Defective TAFI activation in hemophilia A mice is a major contributor to joint bleeding. Blood, 2018, 132, 1593-1603.	1.4	31
38	Role of von Willebrand factor and ADAMTSâ€13 in early brain injury after experimental subarachnoid hemorrhage. Journal of Thrombosis and Haemostasis, 2018, 16, 1413-1422.	3.8	17
39	Elevated factor VIII increases the risk of cerebral venous thrombosis: a case–control study. Journal of Neurology, 2018, 265, 1612-1617.	3.6	15
40	Use of DOAC Stop for elimination of anticoagulants in the thrombin generation assay. Thrombosis Research, 2018, 170, 97-101.	1.7	34
41	Inhibition of the extrinsic or intrinsic coagulation pathway during pneumonia-derived sepsis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 315, L799-L809.	2.9	16
42	Hemostatic changes associate with mortality in hospitalized patients with HIV-associated tuberculosis: a prospective cohort study. Journal of Infectious Diseases, 2017, 215, jiw532.	4.0	19
43	Circulating activated protein C in thrombophilia carriers. Journal of Thrombosis and Thrombolysis, 2017, 43, 361-364.	2.1	1
44	High miR-124-3p expression identifies smoking individuals susceptible to atherosclerosis. Atherosclerosis, 2017, 263, 377-384.	0.8	33
45	Dynamics of von Willebrand factor reactivity in sickle cell disease during vasoâ€occlusive crisis and steady state. Journal of Thrombosis and Haemostasis, 2017, 15, 1392-1402.	3.8	20
46	Association between protein C levels and mortality in patients with advanced prostate, lung and pancreatic cancer. Thrombosis Research, 2017, 154, 1-6.	1.7	10
47	Contact ignition by single-chain XIIa. Blood, 2017, 129, 1411-1412.	1.4	1
48	Coagulation factor XIII-A subunit and activation peptide levels in individuals with established symptomatic acute deep vein thrombosis. Thrombosis Research, 2017, 159, 96-99.	1.7	11
49	Factor V Leiden is associated with increased sperm count. Human Reproduction, 2017, 32, 2332-2339.	0.9	2
50	Novel targets for anticoagulants lacking bleeding risk. Current Opinion in Hematology, 2017, 24, 419-426.	2.5	17
51	Increased Circulating and Urinary Levels of Soluble TAM Receptors in Diabetic Nephropathy. American Journal of Pathology, 2017, 187, 1971-1983.	3.8	16
52	Editorial: Introduction to the Presentations at the Factor XI and the Contact System SSC Session of the ISTH, Montpellier, France, May 27, 2016. Frontiers in Medicine, 2017, 4, 140.	2.6	0
53	Whole exome sequencing in thrombophilic pedigrees to identify genetic risk factors for venous thromboembolism. PLoS ONE, 2017, 12, e0187699.	2.5	14
54	Coagulation factor XI improves host defence during murine pneumonia-derived sepsis independent of factor XII activation. Thrombosis and Haemostasis, 2017, 117, 1601-1614.	3.4	40

#	Article	IF	CITATIONS
55	Increased Von Willebrand factor, decreased ADAMTS13 and thrombocytopenia in melioidosis. PLoS Neglected Tropical Diseases, 2017, 11, e0005468.	3.0	7
56	Activated protein C protects against renal ischaemia/reperfusion injury, independent of its anticoagulant properties. Thrombosis and Haemostasis, 2016, 116, 124-133.	3.4	9
57	Structureâ€function relationships in thrombinâ€activatable fibrinolysis inhibitor. Journal of Thrombosis and Haemostasis, 2016, 14, 633-644.	3.8	46
58	Impact of <scp>HIV</scp> infection on the haemostatic response during sepsis and malaria. British Journal of Haematology, 2016, 173, 918-926.	2.5	8
59	Loss of asthma control and activation of coagulation and fibrinolysis. Clinical and Experimental Allergy, 2016, 46, 422-427.	2.9	8
60	<i>In vivo</i> reversal of the anticoagulant effect of rivaroxaban with fourâ€factor prothrombin complex concentrate. British Journal of Haematology, 2016, 172, 255-261.	2.5	48
61	The influence of corticosteroids on hemostasis in healthy subjects. Journal of Thrombosis and Haemostasis, 2016, 14, 716-723.	3.8	45
62	Prothrombotic state in patients with severe and prednisolone-dependent asthma. Journal of Allergy and Clinical Immunology, 2016, 137, 1727-1732.	2.9	36
63	PO-28 - Protein C levels are associated with mortality in patients with advanced cancer. Thrombosis Research, 2016, 140, S186-S187.	1.7	2
64	Stimulation of thrombin- and plasmin-mediated activation of thrombin-activatable fibrinolysis inhibitor by anionic molecules. Thrombosis Research, 2016, 146, 7-14.	1.7	6
65	Use of an absorbable embolization material for reversible portal vein embolization in an experimental model. British Journal of Surgery, 2016, 103, 1306-1315.	0.3	9
66	The role of ADAMTS13 in acute myocardial infarction: cause or consequence?. Cardiovascular Research, 2016, 111, 194-203.	3.8	24
67	Kinetics of coagulation in ST-elevation myocardial infarction following successful primary percutaneous coronary intervention. Thrombosis Research, 2016, 137, 64-71.	1.7	8
68	The hypercoagulable state in hyperthyroidism is mediated via the thyroid hormone Î ² receptor pathway. European Journal of Endocrinology, 2016, 174, 755-762.	3.7	21
69	Heparin supplement counteracts the prohemostatic effect of prothrombin complex concentrate and factor IX concentrate: An in vitro evaluation. Thrombosis Research, 2016, 139, 102-110.	1.7	7
70	A sustained decrease in plasma fibrinolytic potential following partial liver resection or pancreas resection. Thrombosis Research, 2016, 140, 36-40.	1.7	9
71	Low miR-19b-1-5p expression in isolated platelets after aspirin use is related to aspirin insensitivity. International Journal of Cardiology, 2016, 203, 262-263.	1.7	32
72	Coagulation activation during air travel is not initiated via the extrinsic pathway. British Journal of Haematology, 2015, 169, 903-905.	2.5	4

#	Article	IF	CITATIONS
73	New clues regarding the mysterious mechanism of activated thrombin-activatable fibrinolysis inhibitor self-destruction. Journal of Thrombosis and Haemostasis, 2015, 13, 1081-1083.	3.8	3
74	Fresh frozen plasma transfusion fails to influence the hemostatic balance in critically ill patients with a coagulopathy. Journal of Thrombosis and Haemostasis, 2015, 13, 989-997.	3.8	58
75	No association between <i><scp>A</scp>nnexin <scp>A</scp>5</i> genetic variants and deep venous thrombosis. British Journal of Haematology, 2015, 169, 301-304.	2.5	4
76	A novel mutation in the F5 gene (factor V Amsterdam) associated with bleeding independent of factor V procoagulant function. Blood, 2015, 125, 1822-1825.	1.4	58
77	Factor XIIIa-dependent retention of red blood cells in clots is mediated by fibrin α-chain crosslinking. Blood, 2015, 126, 1940-1948.	1.4	121
78	The plasma levels of protein Z-dependent protease inhibitor increase after gynecological surgery independently of estrogen. Thrombosis Research, 2015, 136, 980-986.	1.7	5
79	Decreased plasma levels of activated factor VII in patients with deep vein thrombosis. Journal of Thrombosis and Haemostasis, 2015, 13, 1320-1324.	3.8	4
80	In vivo increase in thrombin generation by fourâ€factor prothrombin complex concentrate in apixabanâ€ŧreated healthy volunteers. Journal of Thrombosis and Haemostasis, 2015, 13, 1799-1805.	3.8	66
81	Thrombinâ€activatable fibrinolysis inhibitor influences disease severity in humans and mice with pneumococcal meningitis. Journal of Thrombosis and Haemostasis, 2015, 13, 2076-2086.	3.8	12
82	Introduction to the analysis of next generation sequencing data and its application to venous thromboembolism. Thrombosis and Haemostasis, 2015, 114, 920-932.	3.4	10
83	Selective modulation of thrombin-activatable fibrinolysis inhibitor (TAFI) activation by thrombin or the thrombin-thrombomodulin complex using TAFI-derived peptides. Journal of Thrombosis and Haemostasis, 2015, 13, 2093-2101.	3.8	4
84	Active but inoperable thrombin is accumulated in a plasma protein layer surrounding Streptococcus pyogenes. Thrombosis and Haemostasis, 2015, 114, 717-726.	3.4	4
85	Endogenous tissue factor pathway inhibitor has a limited effect on host defence in murine pneumococcal pneumonia. Thrombosis and Haemostasis, 2015, 114, 115-122.	3.4	5
86	Normalization panels for the reliable quantification of circulating microRNAs by RT-qPCR. FASEB Journal, 2015, 29, 3853-3862.	0.5	70
87	Effect of transfusion of fresh frozen plasma on parameters of endothelial condition and inflammatory status in non-bleeding critically ill patients: a prospective substudy of a randomized trial. Critical Care, 2015, 19, 163.	5.8	71
88	Lowering blood glucose during hip surgery does not influence coagulation activation. BBA Clinical, 2015, 3, 227-232.	4.1	6
89	Hemostasis and Fibrinolysis in Delayed Cerebral Ischemia after Aneurysmal Subarachnoid Hemorrhage: A Systematic Review. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 724-733.	4.3	55
90	The cytoprotective effects of endogenous activated protein C reduce activation of coagulation during murine pneumococcal pneumonia and sepsis. Thrombosis Research, 2015, 135, 537-543.	1.7	12

#	Article	IF	CITATIONS
91	Markers of endothelial cell activation and immune activation are increased in patients with severe leptospirosis and associated with disease severity. Journal of Infection, 2015, 71, 437-446.	3.3	17
92	Effect of Puumala hantavirus infection on human umbilical vein endothelial cell hemostatic function: platelet interactions, increased tissue factor expression and fibrinolysis regulator release. Frontiers in Microbiology, 2015, 6, 220.	3.5	28
93	Development of a Hyperactive Primary Hemostatic System During Off-Pump Lung Transplantation Resulting From an Unbalance Between von Willebrand Factor and Its Cleaving Protease ADAMTS13. American Journal of Transplantation, 2015, 15, 1958-1966.	4.7	3
94	Lack of TAFI increases brain damage and microparticle generation after thrombolytic therapy in ischemic stroke. Thrombosis Research, 2015, 136, 445-450.	1.7	15
95	Effect of the oral thrombin inhibitor dabigatran on allergic lung inflammation induced by repeated house dust mite administration in mice. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2015, 309, L768-L775.	2.9	8
96	Pulmonary tuberculosis induces a systemic hypercoagulable state. Journal of Infection, 2015, 70, 324-334.	3.3	48
97	Activated protein C inhibits neutrophil migration in allergic asthma: a randomised trial. European Respiratory Journal, 2015, 46, 1636-1644.	6.7	16
98	Development of a Hypercoagulable Status in Patients Undergoing Off-Pump Lung Transplantation despite Prolonged Conventional Coagulation Tests. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 230-233.	5.6	10
99	Differential In Vitro Inhibition of Thrombin Generation by Anticoagulant Drugs in Plasma from Patients with Cirrhosis. PLoS ONE, 2014, 9, e88390.	2.5	79
100	Individual with Subclinical Atherosclerosis Have Impaired Proliferation of Blood Outgrowth Endothelial Cells, Which Can Be Restored by Statin Therapy. PLoS ONE, 2014, 9, e99890.	2.5	11
101	Individuals with coronary artery disease at a young age and features of the metabolic syndrome have an increased prothrombotic potential. Thrombosis and Haemostasis, 2014, 111, 458-464.	3.4	6
102	The endothelial protein C receptor impairs the antibacterial response in murine pneumococcal pneumonia and sepsis. Thrombosis and Haemostasis, 2014, 111, 970-980.	3.4	9
103	Overexpression of activated protein C hampers bacterial dissemination during pneumococcal pneumonia. BMC Infectious Diseases, 2014, 14, 559.	2.9	9
104	Effect of recombinant ADAMTS-13 on microthrombosis and brain injury after experimental subarachnoid hemorrhage. Journal of Thrombosis and Haemostasis, 2014, 12, 943-947.	3.8	27
105	Altered platelet contents in survivors of early ischemic ventricular fibrillation: Preliminary findings. Platelets, 2014, 25, 71-74.	2.3	0
106	Recent insights into the role of the contact pathway in thrombo-inflammatory disorders. Hematology American Society of Hematology Education Program, 2014, 2014, 60-65.	2.5	39
107	Hyperferritinaemia in Dengue Virus Infected Patients Is Associated with Immune Activation and Coagulation Disturbances. PLoS Neglected Tropical Diseases, 2014, 8, e3214.	3.0	46
108	Utility of thromboelastography and/or thromboelastometry in adults with sepsis: a systematic review. Critical Care, 2014, 18, R30.	5.8	185

#	Article	IF	CITATIONS
109	Mutations in <i>STAP1</i> Are Associated With Autosomal Dominant Hypercholesterolemia. Circulation Research, 2014, 115, 552-555.	4.5	146
110	A role for arginineâ€12 in thrombin–thrombomodulinâ€mediated activation of thrombinâ€activatable fibrinolysis inhibitor. Journal of Thrombosis and Haemostasis, 2014, 12, 1717-1725.	3.8	14
111	Acquired von <scp>W</scp> illebrand syndrome in patients with overt hypothyroidism: a prospective cohort study. Haemophilia, 2014, 20, 326-332.	2.1	28
112	Factor XI Regulates Pathological Thrombus Formation on Acutely Ruptured Atherosclerotic Plaques. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1668-1673.	2.4	47
113	Plasminogen activator inhibitor-1 influences cerebrovascular complications and death in pneumococcal meningitis. Acta Neuropathologica, 2014, 127, 553-564.	7.7	17
114	Evaluation of coagulation activation after Rhinovirus infection in patients with asthma and healthy control subjects: an observational study. Respiratory Research, 2014, 15, 14.	3.6	21
115	Factor XII Regulates the Pathological Process of Thrombus Formation on Ruptured Plaques. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1674-1680.	2.4	108
116	Evaluating the Optimal Timing of Revascularisation in Patients with Transient ST-Segment Elevation Myocardial Infarction: Rationale and Design of the TRANSIENT Trial. Journal of Cardiovascular Translational Research, 2014, 7, 590-596.	2.4	10
117	Activation of coagulation and tissue fibrin deposition in experimental influenza in ferrets. BMC Microbiology, 2014, 14, 134.	3.3	30
118	The influence of HIV infection on coagulation activation during sepsis. International Journal of Infectious Diseases, 2014, 21, 128.	3.3	0
119	Clot stability and fibrin deposition is strongly reduced in mice in which mouse TAFI is replaced by human TAFI. Thrombosis Research, 2014, 133, 1166-1168.	1.7	0
120	No contact, no thrombosis?. Blood, 2014, 123, 1629-1629.	1.4	6
121	Sustained pro-haemostatic activity of rFVIIa in plasma and platelets in non-bleeding pigs may explain the efficacy of a once-daily prophylaxis in humans. Thrombosis and Haemostasis, 2014, 112, 304-310.	3.4	6
122	Optimisation of lupus anticoagulant tests: should test samples always be mixed with normal plasma?. Thrombosis and Haemostasis, 2014, 112, 736-742.	3.4	26
123	C0288: Lack of TAFI Has Deleterious Effect on Experimental Ischemic Stroke: Potential Role of Microparticles. Thrombosis Research, 2014, 133, S5.	1.7	1
124	Treatment with everolimus is associated with a procoagulant state. Thrombosis Research, 2013, 132, 307-311.	1.7	42
125	Endogenous protein C has a protective role during Gram-negative pneumosepsis (melioidosis). Journal of Thrombosis and Haemostasis, 2013, 11, 282-292.	3.8	20
126	Urinary prothrombin fragment 1+2 in patients with venous thrombosis and myocardial infarction. Journal of Thrombosis and Thrombolysis, 2013, 36, 47-49.	2.1	0

#	Article	IF	CITATIONS
127	The Aggregation Potential of the 1–15- and 1–16-Fragments of the Amyloid β Peptide and Their Influence on the Aggregation of Aβ40. Applied Magnetic Resonance, 2013, 44, 1167-1179.	1.2	3
128	Circulating Nucleosomes and Neutrophil Activation as Risk Factors for Deep Vein Thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 147-151.	2.4	193
129	Endogenous α2-Antiplasmin Is Protective during Severe Gram-Negative Sepsis (Melioidosis). American Journal of Respiratory and Critical Care Medicine, 2013, 188, 967-975.	5.6	33
130	Decreased tissue factor pathway inhibitor (<scp>TFPI</scp>)â€dependent anticoagulant capacity in patients with cirrhosis who have decreased protein <scp>S</scp> but normal <scp>TFPI</scp> plasma levels. British Journal of Haematology, 2013, 162, 819-826.	2.5	14
131	VEGF Levels in Plasma in Relation to Platelet Activation, Glycemic Control, and Microvascular Complications in Type 1 Diabetes. Diabetes Care, 2013, 36, 1629-1634.	8.6	40
132	Lamin A/C mutation is independently associated with an increased risk of arterial and venous thromboembolic complications. International Journal of Cardiology, 2013, 168, 472-477.	1.7	33
133	Thrombin-activatable fibrinolysis inhibitor in hypothyroidism and hyperthyroxinaemia. Thrombosis and Haemostasis, 2013, 109, 214-220.	3.4	16
134	An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: Implications for hemostasis and clinical outcome. Hepatology, 2013, 58, 752-761.	7.3	153
135	Overexpression of the Endothelial Protein C Receptor Is Detrimental during Pneumonia-Derived Gram-negative Sepsis (Melioidosis). PLoS Neglected Tropical Diseases, 2013, 7, e2306.	3.0	14
136	The lectin-like domain of thrombomodulin hampers host defence in pneumococcal pneumonia. European Respiratory Journal, 2013, 41, 935-942.	6.7	8
137	Factor Xa Activation of Factor V Is of Paramount Importance in Initiating the Coagulation System. Circulation, 2013, 128, 254-266.	1.6	84
138	Differential Effects of Nonselective Versus Selective β-Blockers on Cardiac Sympathetic Activity and Hemostasis in Patients with Heart Failure. Journal of Nuclear Medicine, 2013, 54, 1733-1739.	5.0	11
139	Clot lysis phenotype and response to recombinant factor <scp>VII</scp> a in plasma of haemophilia A inhibitor patients. British Journal of Haematology, 2013, 162, 827-835.	2.5	10
140	Intrabronchial activated protein C enhances lipopolysaccharide-induced pulmonary responses. European Respiratory Journal, 2013, 42, 188-197.	6.7	10
141	Obesity in haemophilia patients: effect on bleeding frequency, clotting factor concentrate usage, and haemostatic and fibrinolytic parameters. Haemophilia, 2013, 19, 744-752.	2.1	22
142	Statin therapy and levels of hemostatic factors in a healthy population: the Multi-Ethnic Study of Atherosclerosis: a rebuttal. Journal of Thrombosis and Haemostasis, 2013, 11, 1787-1788.	3.8	2
143	Two novel inhibitory anti-human factor XI antibodies prevent cessation of blood flow in a murine venous thrombosis model. Thrombosis and Haemostasis, 2013, 110, 1065-1073.	3.4	30
144	Differences in platelet microRNA profiles after aspirin use are associated with differences in whole blood aggregation and might identify aspirin resistance. European Heart Journal, 2013, 34, P4884-P4884.	2.2	0

#	Article	IF	CITATIONS
145	Overexpression of Activated Protein C is Detrimental During Severe Experimental Gram-Negative Sepsis (Melioidosis)*. Critical Care Medicine, 2013, 41, e266-e274.	0.9	8
146	TAFI deficiency promotes liver damage in murine models of liver failure through defective down-regulation of hepatic inflammation. Thrombosis and Haemostasis, 2013, 109, 948-955.	3.4	19
147	The endothelial protein C receptor and activated protein C play a limited role in host defense during experimental tuberculosis. Thrombosis and Haemostasis, 2013, 109, 726-737.	3.4	7
148	Venous thromboembolism in adults treated for acute lymphoblastic leukaemia: Effect of fresh frozen plasma supplementation. Thrombosis and Haemostasis, 2013, 109, 633-642.	3.4	33
149	Anticoagulation beyond direct thrombin and factor Xa inhibitors: indications for targeting the intrinsic pathway?. Thrombosis and Haemostasis, 2013, 110, 223-232.	3.4	33
150	Endogenous tissue-type plasminogen activator impairs host defense during severe experimental gram-negative sepsis (melioidosis)*. Critical Care Medicine, 2012, 40, 2168-2175.	0.9	19
151	BH3-only protein Noxa regulates apoptosis in activated B cells and controls high-affinity antibody formation. Blood, 2012, 119, 1440-1449.	1.4	33
152	Intact thrombin generation and decreased fibrinolytic capacity in patients with acute liver injury or acute liver failure. Journal of Thrombosis and Haemostasis, 2012, 10, 1312-1319.	3.8	101
153	Microcirculation and atherothrombotic parameters in prolactinoma patients: a pilot study. Pituitary, 2012, 15, 472-481.	2.9	13
154	Recombinant C1-Inhibitor. BioDrugs, 2012, 26, 43-52.	4.6	28
155	Chronic pulmonary embolism in Klippel-Trenaunay syndrome. Journal of the American Academy of Dermatology, 2012, 66, 71-77.	1.2	31
156	Review: Viral infections and mechanisms of thrombosis and bleeding. Journal of Medical Virology, 2012, 84, 1680-1696.	5.0	252
157	Reply from the authors. Hepatology Research, 2012, 42, 1154-1155.	3.4	0
158	The hyperfibrinolytic state of mice with combined thrombinâ€activatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitorâ€1 gene deficiency is critically dependent on TAFI deficiency. Journal of Thrombosis and Haemostasis, 2012, 10, 2555-2562.	3.8	22
159	Effects of the etonogestrel-releasing contraceptive implant inserted immediately postpartum on maternal hemostasis: A randomized controlled trial. Thrombosis Research, 2012, 130, 355-360.	1.7	17
160	Increase in the plasma levels of protein Z-dependent protease inhibitor in normal pregnancies but not in non-pregnant patients with unexplained recurrent miscarriage. Thrombosis and Haemostasis, 2012, 107, 507-512.	3.4	5
161	Recent developments in our understanding of the antiphospholipid syndrome. International Journal of Laboratory Hematology, 2012, 34, 223-231.	1.3	26
162	<i>Factor XIII Val34Leu</i> mutation accelerates the development of fibrosis in patients with chronic hepatitis B and C. Hepatology Research, 2012, 42, 668-676.	3.4	11

#	Article	IF	CITATIONS
163	Clinical practice. European Journal of Pediatrics, 2012, 171, 207-214.	2.7	21
164	Blood transfusion during cardiac surgery is associated with inflammation and coagulation in the lung: a case control study. Critical Care, 2011, 15, R59.	5.8	50
165	The Hemostatic System in Patients With Type 2 Diabetes With and Without Cardiovascular Disease. Clinical and Applied Thrombosis/Hemostasis, 2011, 17, E57-E63.	1.7	23
166	Plasma levels of pentraxin-3, an acute phase protein, are increased during sickle cell painful crisis. Blood Cells, Molecules, and Diseases, 2011, 46, 189-194.	1.4	18
167	Activated human platelet products induce proarrhythmic effects in ventricular myocytes. Journal of Molecular and Cellular Cardiology, 2011, 51, 347-356.	1.9	5
168	Acute Stress Elicited by Bungee Jumping Suppresses Human Innate Immunity. Molecular Medicine, 2011, 17, 180-188.	4.4	36
169	Quantitative trait locus for protein C in a family with thrombophilia. Thrombosis and Haemostasis, 2011, 105, 199-201.	3.4	4
170	Binding characteristics of thrombin-activatable fibrinolysis inhibitor to streptococcal surface collagen-like proteins A and B. Thrombosis and Haemostasis, 2011, 106, 609-616.	3.4	6
171	Diabetes does not influence activation of coagulation, fibrinolysis or anticoagulant pathways in Gram-negative sepsis (melioidosis). Thrombosis and Haemostasis, 2011, 106, 1139-1148.	3.4	13
172	Evolutionary conservation of the lipopolysaccharide binding site of $\hat{1}^22$ -glycoprotein I. Thrombosis and Haemostasis, 2011, 106, 1069-1075.	3.4	34
173	Platelets in Patients with Premature Coronary Artery Disease Exhibit Upregulation of miRNA340* and miRNA624*. PLoS ONE, 2011, 6, e25946.	2.5	86
174	Identification and Characterization of Ixodes scapularis Antigens That Elicit Tick Immunity Using Yeast Surface Display. PLoS ONE, 2011, 6, e15926.	2.5	72
175	Vascular Endothelial Growth Factor in the Circulation in Cancer Patients May Not Be a Relevant Biomarker. PLoS ONE, 2011, 6, e19873.	2.5	43
176	Endothelial dysfunction, platelet activation, thrombogenesis and fibrinolysis in patients with hypertensive crisis. Journal of Hypertension, 2011, 29, 922-927.	0.5	48
177	The hemostatic status of pediatric recipients of adult liver grafts suggests that plasma levels of hemostatic proteins are not regulated by the liver. Blood, 2011, 117, 2070-2072.	1.4	22
178	β2-Glycoprotein I: a novel component of innate immunity. Blood, 2011, 117, 6939-6947.	1.4	101
179	Increased coagulation factor VIII activity in patients with familial hypercholesterolemia. Blood, 2011, 118, 6990-6991.	1.4	11
180	Decreased active von Willebrand factor level owing to shear stress in aortic stenosis patients. Journal of Thrombosis and Haemostasis, 2011, 9, 953-958.	3.8	21

#	Article	IF	CITATIONS
181	High levels of protein C are determined by PROCR haplotype 3. Journal of Thrombosis and Haemostasis, 2011, 9, 969-976.	3.8	17
182	β2â€ClycoproteinÂl: evolution, structure and function. Journal of Thrombosis and Haemostasis, 2011, 9, 1275-1284.	3.8	180
183	Acute respiratory tract infection leads to procoagulant changes in human subjects. Journal of Thrombosis and Haemostasis, 2011, 9, 1432-1434.	3.8	23
184	Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time. Journal of Thrombosis and Haemostasis, 2011, 9, 1657-1659.	3.8	82
185	Influenza vaccination and hemostasis: no sustainable procoagulant effects from 2009 H1N1 influenza vaccine in healthy healthcare workers. Journal of Thrombosis and Haemostasis, 2011, 9, 1659-1661.	3.8	1
186	Alterations in coagulation and fibrinolysis after levothyroxine exposure in healthy volunteers: a controlled randomized crossover study. Journal of Thrombosis and Haemostasis, 2011, 9, 1816-1824.	3.8	40
187	Plasminogen activator inhibitor typeÂl contributes to protective immunity during experimental Gramâ€negative sepsis (melioidosis). Journal of Thrombosis and Haemostasis, 2011, 9, 2020-2028.	3.8	34
188	Induction of antiâ€Î²2â€glycoproteinÂl autoantibodies in mice by proteinÂH of Streptococcus pyogenes. Journal of Thrombosis and Haemostasis, 2011, 9, 2447-2456.	3.8	35
189	Protein C Inhibitor. Seminars in Thrombosis and Hemostasis, 2011, 37, 349-354.	2.7	34
190	Forgotten Factors in Hemostasis and Thrombosis. Seminars in Thrombosis and Hemostasis, 2011, 37, 337-338.	2.7	0
191	β2-Glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood, 2010, 116, 1336-1343.	1.4	247
192	Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood, 2010, 116, 113-121.	1.4	309
193	The effects of an extremely high dose of levothyroxine on coagulation and fibrinolysis. Journal of Thrombosis and Haemostasis, 2010, 8, 1427-1428.	3.8	13
194	Expression patterns of protein C inhibitor in mouse development. Journal of Molecular Histology, 2010, 41, 27-37.	2.2	7
195	Markers of inflammation and coagulation indicate a prothrombotic state in HIV-infected patients with long-term use of antiretroviral therapy with or without abacavir. AIDS Research and Therapy, 2010, 7, 9.	1.7	40
196	Increased sperm count may account for high population frequency of factor V Leiden. Journal of Thrombosis and Haemostasis, 2010, 8, 513-516.	3.8	11
197	Explanations for coagulation activation after air travel. Journal of Thrombosis and Haemostasis, 2010, 8, 971-978.	3.8	25
198	Intact thrombomodulinâ€mediated regulation of fibrinolysis during and after liver transplantation, despite a profoundly defective thrombomodulinâ€mediated regulation of coagulation. Journal of Thrombosis and Haemostasis, 2010, 8, 1646-1649.	3.8	12

#	Article	IF	CITATIONS
199	Hyperglycemia: a prothrombotic factor?. Journal of Thrombosis and Haemostasis, 2010, 8, 1663-1669.	3.8	227
200	Thrombinâ€activatable fibrinolysis inhibitor is degraded by Salmonella enterica and Yersinia pestis. Journal of Thrombosis and Haemostasis, 2010, 8, 2232-2240.	3.8	21
201	Coagulation factor XI as a novel target for antithrombotic treatment. Journal of Thrombosis and Haemostasis, 2010, 8, 2349-2357.	3.8	67
202	Coagulation disorders in patients with severe leptospirosis are associated with severe bleeding and mortality. Tropical Medicine and International Health, 2010, 15, 152-159.	2.3	61
203	The effect of initiating combined antiretroviral therapy on endothelial cell activation and coagulation markers in South African HIV-infected individuals. Thrombosis and Haemostasis, 2010, 104, 1228-1234.	3.4	58
204	Severe malaria is associated with a deficiency of von Willebrand factor cleaving protease, ADAMTS13. Thrombosis and Haemostasis, 2010, 103, 181-187.	3.4	70
205	Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood, 2010, 116, 4684-4692.	1.4	172
206	Urokinase Receptor Is Necessary for Bacterial Defense against Pneumonia-Derived Septic Melioidosis by Facilitating Phagocytosis. Journal of Immunology, 2010, 184, 3079-3086.	0.8	49
207	Activated factor V is a cofactor for the activation of factor XI by thrombin in plasma. Proceedings of the United States of America, 2010, 107, 9083-9087.	7.1	30
208	Systemic Inflammatory Response Syndrome and Compensatory Anti-Inflammatory Response Syndrome in Sepsis. Journal of Innate Immunity, 2010, 2, 379-380.	3.8	33
209	Normal to increased thrombin generation in patients undergoing liver transplantation despite prolonged conventional coagulation tests. Journal of Hepatology, 2010, 52, 355-361.	3.7	191
210	Clinical usefulness of prothrombin fragment 1+2 in patients with suspected pulmonary embolism. Thrombosis Research, 2010, 125, 97-99.	1.7	6
211	The role of thrombin-activatable fibrinolysis inhibitor in diabetic wound healing. Thrombosis Research, 2010, 126, 442-446.	1.7	15
212	Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) Deficient Mice Are Susceptible to Intracerebral Thrombosis and Ischemic Stroke. PLoS ONE, 2010, 5, e11658.	2.5	32
213	Assessment of coagulation and fibrinolysis in families with unexplained thrombophilia. Thrombosis and Haemostasis, 2009, 101, 465-470.	3.4	30
214	The effects of hyperglycaemia on thrombin-activatable fibrinolysis inhibitor. Thrombosis and Haemostasis, 2009, 102, 460-468.	3.4	8
215	The Hemostatic Balance in HIV-Infected Patients with and without Antiretroviral Therapy: Partial Restoration with Antiretroviral Therapy. AIDS Patient Care and STDs, 2009, 23, 1001-1007.	2.5	47
216	Activation of TAFI on the Surface of <i>Streptococcus pyogenes</i> Evokes Inflammatory Reactions by Modulating the Kallikrein/Kinin System. Journal of Innate Immunity, 2009, 1, 18-28.	3.8	33

#	Article	IF	CITATIONS
217	Plasminogen activator inhibitor-1 regulates neutrophil influx during acute pyelonephritis. Kidney International, 2009, 75, 52-59.	5.2	35
218	Recent Developments in Thrombin-Activatable Fibrinolysis Inhibitor Research. Mini-Reviews in Medicinal Chemistry, 2009, 9, 1165-1173.	2.4	14
219	Protein C Inhibitor—A Novel Antimicrobial Agent. PLoS Pathogens, 2009, 5, e1000698.	4.7	34
220	The Receptor for Advanced Glycation End Products Impairs Host Defense in Pneumococcal Pneumonia. Journal of Immunology, 2009, 182, 4349-4356.	0.8	99
221	ROLE OF TOLL-LIKE RECEPTORS 2 AND 4, AND THE RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS IN HIGH-MOBILITY GROUP BOX 1-INDUCED INFLAMMATION IN VIVO. Shock, 2009, 31, 280-284.	2.1	237
222	Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men. Haematologica, 2009, 94, 811-818.	3.5	42
223	Biologic Effects of Simvastatin in Patients with Aneurysmal Subarachnoid Hemorrhage: A Double-Blind, Placebo-Controlled Randomized Trial. Journal of Cerebral Blood Flow and Metabolism, 2009, 29, 1444-1453.	4.3	118
224	Reduced ADAMTS13 Activity in Delayed Cerebral Ischemia after Aneurysmal Subarachnoid Hemorrhage. Journal of Cerebral Blood Flow and Metabolism, 2009, 29, 1734-1741.	4.3	42
225	ApoAlâ€phosphatidylcholine infusion neutralizes the atherothrombotic effects of Câ€reactive protein in humans. Journal of Thrombosis and Haemostasis, 2009, 7, 347-354.	3.8	20
226	β2-Glycoprotein I is incorrectly named apolipoprotein H. Journal of Thrombosis and Haemostasis, 2009, 7, 235-236.	3.8	54
227	The activation peptide of thrombin-activatable fibrinolysis inhibitor: a role in activity and stability of the enzyme?. Journal of Thrombosis and Haemostasis, 2009, 7, 445-452.	3.8	20
228	Venous thrombosis is associated with hyperglycemia at diagnosis: a case–control study. Journal of Thrombosis and Haemostasis, 2009, 7, 945-949.	3.8	40
229	Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease. Haematologica, 2009, 94, 1513-1519.	3.5	241
230	Tumor necrosis factor-α inhibition protects against endotoxin-induced endothelial glycocalyx perturbation. Atherosclerosis, 2009, 202, 296-303.	0.8	136
231	Urokinase Plasminogen Activator Receptor-Deficient Mice Demonstrate Reduced Hyperoxia-Induced Lung Injury. American Journal of Pathology, 2009, 174, 2182-2189.	3.8	12
232	Feedback controversy stops here. Blood, 2009, 114, 235-235.	1.4	10
233	Assessment of coagulation and fibrinolysis in families with unexplained thrombophilia. Thrombosis and Haemostasis, 2009, 101, 465-70.	3.4	6
234	Development of sandwichâ€ŧype ELISAs for the quantification of rat and murine thrombin activatable fibrinolysis inhibitor in plasma. Journal of Thrombosis and Haemostasis, 2008, 6, 132-138.	3.8	9

#	Article	IF	CITATIONS
235	Activation of coagulation with concurrent impairment of anticoagulant mechanisms correlates with a poor outcome in severe melioidosis. Journal of Thrombosis and Haemostasis, 2008, 6, 32-39.	3.8	38
236	Effect of the selective serotonin reuptake inhibitor paroxetine on platelet function is modified by a SLC6A4 serotonin transporter polymorphism. Journal of Thrombosis and Haemostasis, 2008, 6, 2168-2174.	3.8	31
237	The antibacterial activity of peptides derived from human betaâ€2 glycoprotein I is inhibited by protein H and M1 protein from <i>Streptococcus pyogenes</i> . Molecular Microbiology, 2008, 67, 482-492.	2.5	32
238	Nur77 modulates hepatic lipid metabolism through suppression of SREBP1c activity. Biochemical and Biophysical Research Communications, 2008, 366, 910-916.	2.1	55
239	Effects of short-term and long-term danazol treatment on lipoproteins, coagulation, and progression of atherosclerosis: Two clinical trials in healthy volunteers and patients with hereditary angioedema. Clinical Therapeutics, 2008, 30, 2314-2323.	2.5	46
240	Association Between Thrombotic Microangiopathy and Reduced ADAMTS13 Activity in Malignant Hypertension. Hypertension, 2008, 51, 862-866.	2.7	80
241	Platelet-Activating Factor Receptor Contributes to Host Defense againstPseudomonas aeruginosaPneumonia but Is Not Essential for the Accompanying Inflammatory and Procoagulant Response. Journal of Immunology, 2008, 180, 3357-3365.	0.8	16
242	Perioperative hyperinsulinaemic normoglycaemic clamp causes hypolipidaemia after coronary artery surgery. British Journal of Anaesthesia, 2008, 100, 442-450.	3.4	26
243	Endogenous β-Adrenergic Receptors Inhibit Lipopolysaccharide-Induced Pulmonary Cytokine Release and Coagulation. American Journal of Respiratory Cell and Molecular Biology, 2008, 39, 373-379.	2.9	13
244	Crystal structures of TAFI elucidate the inactivation mechanism of activated TAFI: a novel mechanism for enzyme autoregulation. Blood, 2008, 112, 2803-2809.	1.4	69
245	Hyperglycemia enhances coagulation and reduces neutrophil degranulation, whereas hyperinsulinemia inhibits fibrinolysis during human endotoxemia. Blood, 2008, 112, 82-89.	1.4	221
246	Fluid loss does not explain coagulation activation during air travel. Thrombosis and Haemostasis, 2008, 99, 1053-1059.	3.4	31
247	Circulating Erythrocyte-Derived Microparticles Are Associated with Coagulation Activation in Sickle Cell Disease. Blood, 2008, 112, 126-126.	1.4	7
248	Severe Malaria and Leptospirosis Are Associated with a Deficiency of the Von Willebrand Factor Cleaving Protease, ADAMTS13. Blood, 2008, 112, 3912-3912.	1.4	2
249	Thrombin-activatable Fibrinolysis Inhibitor Binds to Streptococcus pyogenes by Interacting with Collagen-like Proteins A and B. Journal of Biological Chemistry, 2007, 282, 24873-24881.	3.4	36
250	Prednisolone Dose-Dependently Influences Inflammation and Coagulation during Human Endotoxemia. Journal of Immunology, 2007, 178, 1845-1851.	0.8	94
251	Effects of CRP infusion on endothelial function and coagulation in normocholesterolemic and hypercholesterolemic subjects. Journal of Lipid Research, 2007, 48, 952-960.	4.2	65
252	Pharmacokinetics and pharmacodynamics of danaparoid during continuous venovenous hemofiltration: a pilot study. Critical Care, 2007, 11, R102.	5.8	20

#	Article	IF	CITATIONS
253	EFFECTS OF INTRA-ABDOMINAL ADMINISTRATION OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR ON COAGULATION, FIBRINOLYSIS AND INFLAMMATORY RESPONSES IN EXPERIMENTAL POLYMICROBIAL PERITONITIS. Shock, 2007, 27, 534-541.	2.1	9
254	High-Density Lipoprotein Attenuates Inflammation and Coagulation Response on Endotoxin Challenge in Humans. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 1153-1158.	2.4	102
255	Alterations in lipoprotein homeostasis during human experimental endotoxemia and clinical sepsis. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2007, 1771, 1429-1438.	2.4	76
256	Tissue factor-dependent blood coagulation is enhanced following delivery irrespective of the mode of delivery. Journal of Thrombosis and Haemostasis, 2007, 5, 2415-2420.	3.8	36
257	Activation of coagulation system during air travel: a crossover study. Lancet, The, 2006, 367, 832-838.	13.7	162
258	Tu-P10:482 Possible mechanism underlying the association between C-reactive protein and cardiovascular risk. Atherosclerosis Supplements, 2006, 7, 291.	1.2	0
259	The effects of continuous venovenous hemofiltration on coagulation activation. Critical Care, 2006, 10, R150.	5.8	26
260	Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: opposite and synergistic effects of factors XI and XII. Blood, 2006, 108, 4045-4051.	1.4	214
261	Effect of Hypobaric Hypoxia, Simulating Conditions During Long-Haul Air Travel, on Coagulation, Fibrinolysis, Platelet Function, and Endothelial Activation. JAMA - Journal of the American Medical Association, 2006, 295, 2251.	7.4	117
262	Predilution Versus Postdilution During Continuous Venovenous Hemofiltration: A Comparison of Circuit Thrombogenesis. ASAIO Journal, 2006, 52, 416-422.	1.6	27
263	Proteomic analysis of high-density lipoprotein. Proteomics, 2006, 6, 721-730.	2.2	169
264	Discovery of thrombin activatable fibrinolysis inhibitor (TAFI). Journal of Thrombosis and Haemostasis, 2006, 4, 257-258.	3.8	1
265	The relationship between ABO blood group and the risk of bleeding during vitamin K antagonist treatment. Journal of Thrombosis and Haemostasis, 2006, 4, 1418-1420.	3.8	24
266	The differential association of conjugated equine estrogen and esterified estrogen with activated protein C resistance in postmenopausal women. Journal of Thrombosis and Haemostasis, 2006, 4, 1701-1706.	3.8	12
267	Vagus nerve stimulation inhibits activation of coagulation and fibrinolysis during endotoxemia in rats. Journal of Thrombosis and Haemostasis, 2006, 4, 1997-2002.	3.8	166
268	Anticoagulant and anti-inflammatory effects after peritoneal lavage with antithrombin in experimental polymicrobial peritonitis. Journal of Thrombosis and Haemostasis, 2006, 4, 2343-2351.	3.8	13
269	Endotoxaemia induces resistance to activated protein C in healthy humans. British Journal of Haematology, 2006, 134, 213-219.	2.5	24
270	Effects on Coagulation and Fibrinolysis Induced by Influenza in Mice With a Reduced Capacity to Generate Activated Protein C and a Deficiency in Plasminogen Activator Inhibitor Type 1. Circulation Research, 2006, 99, 1261-1269.	4.5	77

#	Article	IF	CITATIONS
271	Mechanical ventilation affects alveolar fibrinolysis in LPS-induced lung injury. European Respiratory Journal, 2006, 28, 992-998.	6.7	28
272	Loss of Endothelial Glycocalyx During Acute Hyperglycemia Coincides With Endothelial Dysfunction and Coagulation Activation In Vivo. Diabetes, 2006, 55, 480-486.	0.6	469
273	Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood, 2005, 105, 1102-1105.	1.4	246
274	Role of isoleucine residues 182 and 183 in thrombin-activatable fibrinolysis inhibitor. Journal of Thrombosis and Haemostasis, 2005, 3, 1293-1300.	3.8	10
275	The prognostic value of the D-dimer test in cancer patients treated with and without low-molecular-weight heparin. Journal of Thrombosis and Haemostasis, 2005, 3, 1531-1533.	3.8	17
276	Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. Journal of Thrombosis and Haemostasis, 2005, 3, 1993-1997.	3.8	183
277	Effects of high plasma lipoprotein (a) levels on tissue factor pathway inhibitor and the protein C pathway. Journal of Thrombosis and Haemostasis, 2005, 3, 2123-2125.	3.8	11
278	Alveolar fibrinolytic capacity suppressed by injurious mechanical ventilation. Intensive Care Medicine, 2005, 31, 724-732.	8.2	39
279	Analysis of blood coagulation in mice: pre-analytical conditions and evaluation of a home-made assay for thrombin-antithrombin complexes. Thrombosis Journal, 2005, 3, 12.	2.1	31
280	The value of haemostatic markers in the triage of patients with chest pain presenting with a normal or non-diagnostic ECG. Heart, 2005, 91, 1215-1216.	2.9	1
281	Activation of Inflammation and Coagulation After Infusion of C-Reactive Protein in Humans. Circulation Research, 2005, 96, 714-716.	4.5	208
282	Absence of Thrombin-Activatable Fibrinolysis Inhibitor Protects against Sepsis-Induced Liver Injury in Mice. Journal of Immunology, 2005, 175, 6764-6771.	0.8	56
283	Lipopolysaccharide Is Transferred from High-Density to Low-Density Lipoproteins by Lipopolysaccharide-Binding Protein and Phospholipid Transfer Protein. Infection and Immunity, 2005, 73, 2321-2326.	2.2	129
284	Recombinant human activated protein C resets thrombin generation in patients with severe sepsis - a case control study. Critical Care, 2005, 9, R490.	5.8	28
285	Hypercoagulability in the metabolic syndrome. Current Opinion in Pharmacology, 2005, 5, 155-159.	3.5	157
286	Effects of Clopidogrel on the Rebound Hypercoagulable State After Heparin Discontinuation in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology, 2005, 46, 1582-1583.	2.8	17
287	Pentoxifylline reduces fibrin deposition and prolongs survival in neonatal hyperoxic lung injury. Journal of Applied Physiology, 2004, 97, 2014-2019.	2.5	33
288	Anti-Inflammatory and Anticoagulant Effects of Pravastatin in Patients With Type 2 Diabetes. Diabetes Care, 2004, 27, 468-473.	8.6	39

17

#	Article	IF	CITATIONS
289	Generation and Characterization of a Highly Stable Form of Activated Thrombin-activable Fibrinolysis Inhibitor. Journal of Biological Chemistry, 2004, 279, 6620-6628.	3.4	21
290	Absence of mutations in the PCI gene in subfertile men. Molecular Human Reproduction, 2004, 10, 807-813.	2.8	10
291	Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. British Journal of Haematology, 2004, 124, 653-658.	2.5	99
292	Recombinant nematode anticoagulant protein c2, an inhibitor of tissue factor/factor VIIa, attenuates coagulation and the interleukin-10 response in human endotoxemia. Journal of Thrombosis and Haemostasis, 2004, 2, 65-70.	3.8	36
293	Tumor growth and metastasis are not affected in thrombin-activatable fibrinolysis inhibitor-deficient mice. Journal of Thrombosis and Haemostasis, 2004, 2, 769-779.	3.8	19
294	Mechanism of action of carboxypeptidase U: staying above the threshold. Journal of Thrombosis and Haemostasis, 2004, 2, 414-415.	3.8	1
295	Protein C and S and inflammation in sickle cell disease. American Journal of Hematology, 2004, 76, 26-32.	4.1	31
296	New insights into factors affecting clot stability: a role for thrombin activatable fibrinolysis inhibitor (TAFI; plasma procarboxypeptidase B, plasma procarboxypeptidase U, procarboxypeptidase R). Seminars in Hematology, 2004, 41, 13-19.	3.4	37
297	Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation*. Critical Care Medicine, 2004, 32, 2416-2421.	0.9	419
298	Thrombomodulin mutant mice with a strongly reduced capacity to generate activated protein C have an unaltered pulmonary immune response to respiratory pathogens and lipopolysaccharide. Blood, 2004, 103, 1702-1709.	1.4	111
299	Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial. Blood, 2004, 103, 927-933.	1.4	135
300	Dominant factor XI deficiency caused by mutations in the factor XI catalytic domain. Blood, 2004, 104, 128-134.	1.4	92
301	The Role of the Fibrinolytic System in Corneal Angiogenesis. Angiogenesis, 2003, 6, 311-316.	7.2	15
302	Procoagulant protein levels are differentially increased during human endotoxemia. Journal of Thrombosis and Haemostasis, 2003, 1, 1019-1023.	3.8	43
303	Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R,) Tj ETQq1	1.0.78431 3.8	14.rgBT /O∨ 155
304	Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombin-activatable fibrinolysis inhibitor. Journal of Thrombosis and Haemostasis, 2003, 1, 2087-2096.	3.8	82
305	Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux. Journal of Thrombosis and Haemostasis, 2003, 1, 2368-2373.	3.8	70
306	The impact on coagulation of an intravenous loading dose in addition to a subcutaneousregimen of low-molecular-weight heparinin the initial treatment of acute coronary syndromes. Journal of the American College of Cardiology, 2003, 42, 424-427.	2.8	14

#	Article	IF	CITATIONS
307	Potential Role of Platelets in Endothelial Damage Observed During Treatment With Cisplatin, Gemcitabine, and the Angiogenesis Inhibitor SU5416. Journal of Clinical Oncology, 2003, 21, 2192-2198.	1.6	113
308	Effects of IC14, an Anti D14 Antibody, on Coagulation and Fibrinolysis during Lowâ€Grade Endotoxemia in Humans. Journal of Infectious Diseases, 2003, 187, 55-61.	4.0	39
309	Distribution and Kinetics of Lipoprotein-Bound Lipoteichoic Acid. Infection and Immunity, 2003, 71, 3280-3284.	2.2	86
310	Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets. Blood, 2003, 101, 4844-4846.	1.4	102
311	Amyloid endostatin induces endothelial cell detachment by stimulation of the plasminogen activation system. Molecular Cancer Research, 2003, 1, 561-8.	3.4	30
312	Characterization of the H-kininogen-binding Site on Factor XI. Journal of Biological Chemistry, 2002, 277, 4892-4899.	3.4	64
313	Analysis of Coagulation Cascade and Endothelial Cell Activation During Inhibition of Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Pathway in Cancer Patients. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1500-1505.	2.4	141
314	Ability of Recombinant Factor VIIa to Reverse the Anticoagulant Effect of the Pentasaccharide Fondaparinux in Healthy Volunteers. Circulation, 2002, 106, 2550-2554.	1.6	311
315	Effect of second- and third-generation oral contraceptives on fibrinolysis in the absence or presence of the factor V Leiden mutation. Blood Coagulation and Fibrinolysis, 2002, 13, 373-381.	1.0	15
316	Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood, 2002, 99, 175-179.	1.4	159
317	Effects of Second and Third Generation Oral Contraceptives and their Respective Progestagens on the Coagulation System in the Absence or Presence of the Factor V Leiden Mutation. Thrombosis and Haemostasis, 2002, 87, 199-205.	3.4	58
318	Plasmin-Mediated Activation and Inactivation of Thrombin-Activatable Fibrinolysis Inhibitorâ€. Biochemistry, 2002, 41, 6688-6696.	2.5	71
319	Role of Zinc Ions in Activation and Inactivation of Thrombin-Activatable Fibrinolysis Inhibitor. Biochemistry, 2002, 41, 1211-1216.	2.5	20
320	Rebound thrombin generation after heparin therapy in unstable angina. Journal of the American College of Cardiology, 2002, 39, 811-817.	2.8	54
321	No effect of acenocoumarol therapy on levels of endothelial activation markers in sickle cell disease. American Journal of Hematology, 2002, 71, 53-55.	4.1	10
322	Protein C inhibitor (plasminogen activator inhibitor-3) and the risk of venous thrombosis. British Journal of Haematology, 2002, 118, 604-609.	2.5	15
323	Activation of coagulation factor XI, without detectable contact activation in dengue haemorrhagic fever. British Journal of Haematology, 2001, 113, 94-99.	2.5	38
324	Complexes of anti-prothrombin antibodies and prothrombin cause lupus anticoagulant activity by competing with the binding of clotting factors for catalytic phospholipid surfaces. British Journal of Haematology, 2001, 113, 621-629.	2.5	66

#	Article	IF	CITATIONS
325	Reduced activity of TAFI (thrombinâ€activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia. British Journal of Haematology, 2000, 108, 518-523.	2.5	66
326	Protein C inhibitor in platelets?. Blood, 2000, 95, 1880-1881.	1.4	0
327	C4b-Binding Protein Protects Coagulation Factor Va from Inactivation by Activated Protein C. Biochemistry, 2000, 39, 14543-14548.	2.5	13
328	R-205. Protein C inhibitor/plasminogen activator inhibitor-3 is present in the mouse ovary and is down-regulated by human chorionic gonadotrophin treatment. Human Reproduction, 1999, 14, 370-371.	0.9	0
329	Binding of amyloid β precursor protein to coagulation factor XIa in vivo may favour haemorrhagic stroke. Journal of Neurology, 1998, 245, 111-115.	3.6	6
330	Inhibition of serine proteases by reactive site mutants of protein C inhibitor (plasminogen activator) Tj ETQq0 0 C) rgBT /Ove	erlock 10 Tf S
331	Factor XI Activation by Meizothrombin: Stimulation by Phospholipid Vesicles Containing both Phosphatidylserine and Phosphatidylethanolamine. Thrombosis and Haemostasis, 1997, 78, 834-839.	3.4	27
332	Role of the A+ Helix in Heparin Binding to Protein C Inhibitor. Thrombosis and Haemostasis, 1996, 75, 760-766.	3.4	32
333	Effect of Heparin on the Activation of Factor XI by Fibrin-bound Thrombin. Thrombosis and Haemostasis, 1996, 76, 347-353.	3.4	15
334	The Interaction of Protein S with the Phospholipid Surface Is Essential for the Activated Protein C-independent Activity of Protein S. Thrombosis and Haemostasis, 1996, 76, 397-403.	3.4	63
335	Apple four in human blood coagulation factor XI mediates dimer formation. Biochemistry, 1992, 31, 4680-4684.	2.5	87
336	Inhibition of human blood coagulation factor XIa by C.hivin.1 inhibitor. Biochemistry, 1988, 27, 959-963.	2.5	34
337	Inactivation of human plasma kallikrein and factor XIa by protein C inhibitor. Biochemistry, 1988, 27, 4231-4237.	2.5	122
338	Oral contraceptives reduce total protein S, but not free protein S Thrombosis Research, 1987, 45, 109-114.	1.7	45
339	Inhibition of human blood coagulation factor Xa by .alpha.2-macroglobulin. Biochemistry, 1987, 26, 5932-5937.	2.5	37
340	Characterization of human protein S. Thrombosis Research, 1986, 41, 135.	1.7	1
341	Analysis of tomour-localizing haematoporhyrin derivative by high-performance liquid chromatography and fast-atom bombardment mass spectrometry. Journal of Chromatography A, 1986, 352, 231-239.	3.7	13
342	Nanobodies against factor <scp>XI</scp> apple 3 domain inhibit binding of factor <scp>IX</scp> and reveal a novel binding site for high molecular weight kininogen. Journal of Thrombosis and Haemostasis, 0, , .	3.8	5